Latest news

• FDA restricts use of certain antibody treatments for COVID-19

  The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that

• US regulators set to approve oral antiviral against COVID-19

  The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next. ... Oral medications like molnupiravir and Paxlovid are significantly more convenient than the

• Pfizer's oral antiviral Paxlovid significantly cuts risk of severe COVID-19

  Merck’s Lagevrio (molnupiravir) -3CL protease inhibitor, approved in the UK last week, was originally developed to treat influenza.

• UK’s MHRA approves first oral antiviral against COVID-19

  The approval is based on results from the phase 3 MOVe-OUT clinical trial, which showed that molnupiravir reduced the risk of hospitalisation or death by approximately 50% against placebo. ... The US government has already placed an order for1.7 million

• Merck’s COVID-19 antiviral under review in Europe by EMA

  If approved, molnupiravir would be the first oral antiviral for use against COVID-19 in Europe. ... An interim analysis showed that molnupiravir reduced the risk of hospitalisation or death by approximately 50% against placebo.